QQ客服 官方微博 反馈留言

	Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‑blinded, placebo‑controlled, phase II clinical trial
	Xu Ruihua; Shen Lin; Wang Keming; Wu Gang; Shi Chunmei; Ding Kefeng; Lin Lizhu; Wang Jinwan; Xiong Jianping; Wu Changping
	2017
卷号	36期号:12页码:677-685
关键词	Colorectal cancer Famitinib Efficacy Safety
URL标识	查看原文
收录类别	CSCD
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6369664
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Xu Ruihua,Shen Lin,Wang Keming,et al. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‑blinded, placebo‑controlled, phase II clinical trial[J],2017,36(12):677-685.
APA	Xu Ruihua.,Shen Lin.,Wang Keming.,Wu Gang.,Shi Chunmei.,...&Yu Hao.(2017).Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‑blinded, placebo‑controlled, phase II clinical trial.,36(12),677-685.
MLA	Xu Ruihua,et al."Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double‑blinded, placebo‑controlled, phase II clinical trial".36.12(2017):677-685.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。